XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer

Gynecologic Oncology

Volumn 111, Issue 3, 2008, Pages 509-515

  Kim, Kidong ^a   Kang, Soon Beom ^b   Chung, Hyun Hoon ^b   Kim, Jae Weon ^b   Park, Noh Hyun ^b   Song, Yong Sang ^b  

^a Korea Cancer Center Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Dose response relationship; Drug; Drug therapy; Neoadjuvant therapy; Polymorphism; Single nucleotide; Uterine cervical neoplasms

Indexed keywords

ARGININE; CARBOPLATIN; CISPLATIN; CYTOSINE; EPIRUBICIN; FLUOROURACIL; GAMMA INTERFERON; ISOLEUCINE; PACLITAXEL; PLATINUM; THYMINE; TRYPTOPHAN; UFT; VALINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DNA-BINDING PROTEINS; EPIRUBICIN; FEMALE; FLUOROURACIL; GAMMA-GLUTAMYL HYDROLASE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; INTERFERON-GAMMA; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NADP); MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 56449096906     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.08.034     Document Type: Article

References (20)

1. Petsuksiri J., Chansilpa Y., Therasakvichya S., Suntornpong N., Thephamongkhol K., et al. Treatment options in bulky stage IB cervical carcinoma. Int. J. Gynecol. Cancer (2008) 10.1111/j.1525-1438.2008.01195.x
2. Cai H.B., Chen H.Z., and Yin H.H. Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer. J. Obstet. Gynaecol. Res. 32 (2006) 315-323
3. Eddy G.L., Bundy B.N., Creasman W.T., Spirtos N.M., Mannel R.S., Hannigan E., et al. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol. Oncol. 106 (2007) 362-369
4. Napolitano U., Imperato F., Mossa B., Framarino M.L., Marziani R., and Marzetti L. The role of neoadjuvant chemotherapy for squamous cell cervical cancer (Ib-IIIb): a long-term randomized trial. Eur. J. Gynaecol. Oncol. 24 (2003) 51-59
5. Sardi J.E., Giaroli A., Sananes C., Ferreira M., Soderini A., Bermudez A., et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol. Oncol. 67 (1997) 61-69
6. Lai C.H., Hsueh S., Chang T.C., Tseng C.J., Huang K.G., Chou H.H., et al. Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy. Gynecol. Oncol. 64 (1997) 456-462
7. Panici P.B., Scambia G., Baiocchi G., Greggi S., Ragusa G., Gallo A., et al. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival. Cancer 67 (1991) 372-379
8. Chung H.H., Kim M.K., Kim J.W., Park N.H., Song Y.S., Kang S.B., and Lee H.P. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol. Oncol. 103 (2006) 1031-1037
9. Wang Z.H., Miao X.P., Tan W., Zhang X.R., Xu B.H., and Lin D.X. [Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer]. Ai. Zheng. 23 (2004) 865-868
10. Beeghly A., Katsaros D., Chen H., Fracchioli S., Zhang Y., Massobrio M., et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol. Oncol. 100 (2006) 330-337
11. Efferth T., and Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther. 107 (2005) 155-176
12. Goode E.L., Ulrich C.M., and Potter J.D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 1513-1530
13. Li D., Frazier M., Evans D.B., Hess K.R., Crane C.H., Jiao L., et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J. Clin. Oncol. 24 (2006) 1720-1728
14. Li D., Li Y., Jiao L., Chang D.Z., Beinart G., Wolff R.A., et al. Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int. J. Cancer 120 (2007) 1748-1754
15. Chu E., and Allegra C.J. Mechanisms of clinical resistance to 5-fluorouracil chemotherapy. Cancer Treat Res. 87 (1996) 175-195
16. Dervieux T., Kremer J., Lein D.O., Capps R., Barham R., Meyer G., et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14 (2004) 733-739
17. He P., Varticovski L., Bowman E.D., Fukuoka J., Welsh J.A., Miura K., et al. Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum. Pathol. 35 (2004) 1196-1209
18. Sardi J., Sananes C., Giaroli A., Maya G., and di Paola G. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol. Oncol. 38 (1990) 486-493
19. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur. J. Cancer 39 (2003) 2470-2486
20. Committee on Practice B-G. ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas, number 35, May 2002. Obstet. Gynecol. 99 (2002) 855-867